Related references
Note: Only part of the references are listed.Impact of Final Activated Clotting Time After Transradial Coronary Stenting With Maximal Antiplatelet Therapy
Olivier F. Bertrand et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
Gilles Montalescot et al.
EUROPEAN HEART JOURNAL (2008)
The CIAO (coronary interventions antiplatelet-based only) study
Eugenio Stabile et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions -: Appropriateness of including bleeding as a component of a quadruple end point
Gjin Ndrepepa et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention
Adnan Kastrati et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Bivalirudin during primary PCI in acute myocardial infarction
Gregg W. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Efficacy and safety of triple antiplatelet therapy with and without concomitant anticoagulation during elective percutaneous coronary intervention (the REMOVE trial)
Rafael Valencia et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention - The SEPIA-PCI trial
Marc Cohen et al.
CIRCULATION (2007)
Clinical end points in coronary stent trials - A case for standardized definitions
Donald E. Cutlip et al.
CIRCULATION (2007)
Bivalirudin for patients with acute coronary syndromes
Gregg W. Stone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Guidelines for percutaneous coronary interventions -: The task force for percutaneous coronary interventions of the European Society of Cardiology
S Silber et al.
EUROPEAN HEART JOURNAL (2005)
Elective percutaneous coronary intervention using broad-spectrum antiplatelet therapy (eptifibatide, clopidogrel, and aspirin) alone, without scheduled unfractionated heparin or other antithrombin therapy
SJ Denardo et al.
AMERICAN HEART JOURNAL (2005)
Relationship between activated clotting time and ischemic or hemorrhagic complications - Analysis of 4 recent randomized clinical trials of percutaneous coronary intervention
SJ Brener et al.
CIRCULATION (2004)
Association of an activated clotting time ≤250 seconds with adverse event rates after percutaneous coronary intervention using tirofiban and heparin (A TACTICS-TIMI 18 substudy)
DS Pinto et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention - REPLACE-2 Randomized Trial
AM Lincoff et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Relationship between heparin anticoagulation and clinical outcomes in coronary stent intervention - Observations from the ESPRIT trial
TR Tolleson et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2003)
Current perspectives on British use of adjunctive therapies during coronary interventions
N Swanson et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2001)
Minimal heparinization in coronary angioplasty - How much heparin is really warranted?
E Kaluski et al.
AMERICAN JOURNAL OF CARDIOLOGY (2000)
Share Paper
